CClinicalTrials.gg
CompletedNCT03658590Updated Sep 5, 2018

Dexamethasone and Induction of Delivery

A Phase 1 interventional study of Dexamethasone and Distilled Water in Induction of Labor Affected Fetus / Newborn, sponsored by samar sayed el sayed. Completed at 1 site in Egypt. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-09-05.

Sponsored by samar sayed el sayed · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Apr 2018, 8 years 5 months ago, and no results have been posted to the registry.
  • Registered 7 months after the study started (first participant enrolled Jan 2018, registered Aug 2018).
Phase
Phase 1
Study type
Interventional
Enrollment
102
Allocation
Randomized
Sex
Female
01

Study summary

This study aims to evaluate the effect of intravenous injection of a single dose of dexamethasone in shortening the duration interval between initiation of labor induction and delivery of the fetus in primigravida full-term pregnancy.

Read the detailed description

Research hypothesis:

In full term primigravidae undergoing induction of labor, the use of a single dose of dexamethasone (8mg) intra-venously will help in shortening the duration interval between initiation of labor induction and delivery of the fetus.

Research question:

In full term primigravidae undergoing induction of labor, does the use of intra-venous dexamethasone play a role in shortening the duration interval between initiation of labor induction and delivery of the fetus?

Patients and Methods

Type of study:

Double blind randomized controlled trial.

Study settings:

Site: Ain Shams Maternity Hospital Study duration: 6 months

Study population:

One hundred and two pregnant women will be recruited in this study from women attending the emergency room department of obstetrics and gynecology at Ain Shams University.

Inclusion criteria:

Primiparity Singleton pregnancy Gestational age i.e. 40 weeks or more by date or 1st trimestric ultrasound. Bishop score of 4 or greater. Longitudinal lie. Vertex presentation. Intact membranes

Exclusion criteria:

Refused consent Malpresentation. Multiple pregnancies. Active phase of labour. Rupture of membranes (ROM). Cephalo-pelvic disproportion. Previous C-section or myomectomy operation. Known contraindication or hypersensitivity to Dexamethasone. Fetal distress. IUFD Current maternal disorder e.g. diabetes mellitus and pregnancy induced hypertension.

Over distended abdomen e.g. fetal macrosomia or polyhydramonus suggested by ultrasound.

Ante-partum hemorrhage e.g. placenta previa, accidental hemorrhage.

These criteria will be assessed at first during the initial evaluation in the delivery suite as follows:

History:

Personal, menstrual, obstetric, past and family history will be taken. History of present pregnancy will be taken including the first day of last menstrual period, duration of pregnancy, warning symptoms as headache, visual symptoms, edema of face and fingers, excessive vomiting, heart burn, epigastric pain, vaginal bleeding, decreased fetal movements, edema of the lower limbs and history of any drug intake.

Examination:

  1. General examination:vital signs, chest, heart and lower limb examination.
  2. Abdominal examination: for assessment of fundal level, presentation, expected fetal weight, fetal heart rate and presence of scars of previous operations as cesarean section or myomectomy.
  3. Vaginal examination: for assessment of cervical dilatation and effacement at the beginning, state of fetal membranes, station of fetal head, position of fetal head and pelvic adequacy.

Investigations:

  1. Laboratory: blood grouping, Rh typing, complete blood count.
  2. Abdominal ultrasound: to confirm the gestational age, fetal number, viability, presentation, position, estimated fetal weight, and to detect the grade of placental maturity, amount and turbidity of liquor.
  3. CTG: application of CTG half an hour to all participates before starting any intervention.

Enrollment and Allocation of the patients:

After approval of health ethical committee in Ain Shams Hospital and after the initial evaluation, women who fulfilled the appropriate inclusion and exclusion criteria will be invited to participate in the study, a verbal consent will be obtained from each candidate after explanation of the procedure in details.

Randomization:

The eligible 102 women will be randomized into one of the following two groups:

  1. Group D (study group): including 51 women who will receive a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously.
  2. Group P (control group): including 51 women who will receive a prefilled syringe with two milliliters of distilled water intravenously.

No cervical ripping agent will be used for induction of labor in either group. Randomization is performed using a computer-generated randomization system. 102 opaque envelopes will be numbered serially; each envelope will contain the corresponding letter in the randomization table, and when the first pregnant woman arrived, the first envelope will be opened and the pregnant woman will be allocated to the group according to the inside letter.

02

Conditions studied

  • Induction of Labor Affected Fetus / Newborn
03

In context

Lead sponsor

This is the only study on the registry with samar sayed el sayed as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Primiparity
  • Singleton pregnancy
  • Gestational age i.e. 40 weeks or more by date or 1sttrimestric ultrasound.
  • Bishop score of 4 or greater.
  • Longitudinal lie.
  • Vertex presentation.
  • Intact membranes

Exclusion criteria

Exclusion Criteria:

  • Refused consent
  • Malpresentation.
  • Multiple pregnancies.
  • Active phase of labour.
  • Rupture of membranes (ROM).
  • Cephalo-pelvic disproportion.
  • Previous C-section or myomectomy operation.
  • Known contraindication or hypersensitivity to Dexamethasone.
  • Fetal distress.
  • IUFD
  • Current maternal disorder e.g. diabetes mellitus and pregnancy induced hypertension.
  • Over distended abdomen e.g. fetal macrosomia or polyhydramonus suggested by ultrasound.
  • Ante-partum hemorrhage e.g. placenta previa, accidental hemorrhage.
05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
102 participants (actual)

Study arms

  • Active comparator
    Group D

    including 51 women who will receive a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously.

    Drug: Dexamethasone

  • Placebo comparator
    Group P

    including 51 women who will receive a prefilled syringe with two milliliters of distilled water intravenously.

    Drug: Distilled Water

Interventions

  • DrugDexamethasone

    a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously

    Also known as: Drug group

  • DrugDistilled Water

    a prefilled syringe with two milliliters of distilled water intravenously.

    Also known as: Placebo group

06

What researchers measure

Primary outcomes

  1. The interval between the initiation of induction and the delivery of the fetus.

    Mean time of interval between the initiation of induction and the delivery of the fetus in the two groups.

    Time frame: Up to 1 day

Secondary outcomes

  1. The duration of the first stage of labor (Partographic representation will do for each participant).

    Mean time of duration of the first stage of labor in the two groups.

    Time frame: Up to 1 hour

  2. The duration of the second stage of labor.

    Mean time of duration of the second stage of labor in the two groups.

    Time frame: Up to 2 hours

  3. The duration of the third stage of labor.

    Mean time of duration of the third stage of labor in the two groups.

    Time frame: Up to 30 minutes

  4. The neonatal outcome by APGAR score.

    Mean of APGAR score at 1 and 5 minutes for fetus in the two groups.

    Time frame: at 1 and 5 minutes

  5. Any postpartum maternal adverse effects (e.g. vital sing abnormality, any maternal postpartum hemorrhage and central nervous system manifestation).

    Percentage of postpartum adverse effects in both group.

    Time frame: Up to 1 day

07

Study locations

1 site
  • Ain Shams University
    Cairo, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03658590
Lead sponsor
samar sayed el sayed
Responsible party
samar sayed el sayed (Gynecologist and Obstetrician, Ain Shams University) — Sponsor-investigator
First posted
Sep 5, 2018
Start date
Jan 1, 2018
Primary completion
Apr 15, 2018
Completion
Jun 30, 2018
Last update
Sep 5, 2018

Study contacts

Tarek F Tamara, MD
study chair · Ain Shams University
Amgad E Abou Gamrah, MD
study director · Ain Shams University
Gihan E Elhawwary, MD
principal investigator · Ain Shams University

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion